Literature DB >> 19958125

Microplasmin degrades fibronectin and laminin at vitreoretinal interface and outer retina during enzymatic vitrectomy.

Wu Chen1, Wei Mo, Ke Sun, Xin Huang, Yan-lin Zhang, Hou-yan Song.   

Abstract

PURPOSE: To determine whether intravitreal administration of microplasmin (microPlm) will degrade fibronectin (FN) and laminin (LN) in rat retina during microPlm-induced posterior vitreous detachment (PVD).
METHODS: Increasing doses of microPlm, from 0.01 U to 0.03 U, were injected into the left eyes of 60 Sprague-Dawley rats to induce PVD. The right eyes were injected with the same volume of balanced salt solution (BSS). Histochemistry, scanning electron microscopy (SEM), and phase contrast microscopy were performed after 1 day and 7 days, to assess the remnant vitreous cortex. The FN and LN level located at the vitreoretinal interface and the outer retina were detected by immunohistochemistry.
RESULTS: microPlm induced complete PVD in a dose-dependent fashion, without internal limiting membrane (ILM) damage (P = 0.0001, r = -0.479). The FN and LN in the photoreceptor cell layer (PCL) were completely degraded in all microPlm-treated eyes. In eyes with complete PVD, the FN, but not the LN, was completely removed from the ILM by microPlm treatment.
CONCLUSION: Intravitreal injection of microplasmin degraded FN and LN at the vitreoretinal junction as well as at the outer retina.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19958125     DOI: 10.3109/02713680903308487

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  17 in total

1.  Acute ocriplasmin retinopathy.

Authors:  Mark W Johnson; Abigail T Fahim; Rajesh C Rao
Journal:  Retina       Date:  2015-06       Impact factor: 4.256

2.  Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice.

Authors:  Ricarda G Schumann; Julian Langer; Denise Compera; Katharina Luedtke; Markus M Schaumberger; Thomas Kreutzer; Wolfgang J Mayer; Armin Wolf; Siegfried G Priglinger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-28       Impact factor: 3.117

3.  ELLIPSOID ZONE MAPPING AND OUTER RETINAL CHARACTERIZATION AFTER INTRAVITREAL OCRIPLASMIN.

Authors:  Yuji Itoh; Justis P Ehlers
Journal:  Retina       Date:  2016-12       Impact factor: 4.256

Review 4.  Ocriplasmin: a review of its use in patients with symptomatic vitreomacular adhesion.

Authors:  Yahiya Y Syed; Sohita Dhillon
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

5.  Acute loss of vision after an intravitreal injection ocriplasmin: a functional evolutionary study for 1-year follow-up.

Authors:  Francisco Gómez-Ulla; Manuel F Bande; Maximino Abraldes
Journal:  Doc Ophthalmol       Date:  2015-11-06       Impact factor: 2.379

6.  Osteopontin and fibronectin levels are decreased in vitreous of autoimmune uveitis and retinal expression of both proteins indicates ECM re-modeling.

Authors:  Cornelia A Deeg; Christina Eberhardt; Florian Hofmaier; Barbara Amann; Stefanie M Hauck
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

Review 7.  Ocriplasmin for symptomatic vitreomacular adhesion: an evidence-based review of its potential.

Authors:  Su Jeong Song; William E Smiddy
Journal:  Core Evid       Date:  2014-03-21

Review 8.  Ocriplasmin for vitreoretinal diseases.

Authors:  Irena Tsui; Carolyn K Pan; Ehsan Rahimy; Steven D Schwartz
Journal:  J Biomed Biotechnol       Date:  2012-10-14

Review 9.  Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treatment.

Authors:  D H W Steel; A J Lotery
Journal:  Eye (Lond)       Date:  2013-10       Impact factor: 3.775

10.  Post hoc analysis of ellipsoid zone changes beyond the central subfield in symptomatic vitreomacular adhesion patients from the OASIS trial.

Authors:  Swetha Bindu Velaga; Muneeswar Gupta Nittala; Michael S Ip; Luc Duchateau; SriniVas R Sadda
Journal:  BMJ Open Ophthalmol       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.